SG Americas Securities LLC Acquires Shares of 352,276 OPKO Health, Inc. (NASDAQ:OPK)

SG Americas Securities LLC purchased a new position in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 352,276 shares of the biotechnology company's stock, valued at approximately $585,000. SG Americas Securities LLC owned 0.05% of OPKO Health at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the business. Barclays PLC grew its stake in OPKO Health by 68.7% during the 4th quarter. Barclays PLC now owns 916,368 shares of the biotechnology company's stock worth $1,347,000 after purchasing an additional 373,032 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of OPKO Health by 94.7% in the 4th quarter. Bank of America Corp DE now owns 581,582 shares of the biotechnology company's stock valued at $855,000 after buying an additional 282,844 shares during the period. Two Sigma Investments LP grew its position in shares of OPKO Health by 136.1% during the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock worth $2,422,000 after buying an additional 949,671 shares in the last quarter. Norges Bank purchased a new stake in shares of OPKO Health during the fourth quarter worth approximately $1,657,000. Finally, Millennium Management LLC raised its holdings in OPKO Health by 85.3% in the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock valued at $6,745,000 after acquiring an additional 2,112,382 shares in the last quarter. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Stock Down 1.6%

Shares of OPKO Health stock traded down $0.02 during trading hours on Wednesday, hitting $1.27. The company had a trading volume of 1,528,592 shares, compared to its average volume of 3,872,470. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.49 and a quick ratio of 2.28. The company's 50-day moving average is $1.34 and its two-hundred day moving average is $1.51. The company has a market cap of $1.01 billion, a P/E ratio of -18.14 and a beta of 1.39. OPKO Health, Inc. has a twelve month low of $1.19 and a twelve month high of $2.04.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.03). The company had revenue of $149.90 million during the quarter, compared to analysts' expectations of $163.13 million. OPKO Health had a negative net margin of 5.66% and a negative return on equity of 2.85%. OPKO Health's revenue was down 13.7% on a year-over-year basis. During the same period last year, the firm earned ($0.12) earnings per share. Analysts anticipate that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

OPK has been the subject of several analyst reports. Wall Street Zen cut shares of OPKO Health from a "hold" rating to a "sell" rating in a report on Monday, May 5th. Barrington Research reiterated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research note on Thursday, May 1st. JPMorgan Chase & Co. initiated coverage on OPKO Health in a report on Friday, April 25th. They issued a "neutral" rating on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $3.00 price target on shares of OPKO Health in a report on Monday, April 7th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $2.75.

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock in a transaction that occurred on Thursday, April 10th. The stock was purchased at an average price of $1.36 per share, for a total transaction of $170,000.00. Following the transaction, the chief executive officer now directly owns 214,001,448 shares in the company, valued at $291,041,969.28. This trade represents a 0.06% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders bought 500,000 shares of company stock valued at $775,000. Insiders own 49.69% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.